(Q38349512)

2 September 2017

Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes (English)

1 reference

2 September 2017

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.00331.2003

19 March 2024

author name string

Geri Sawada

2

1 reference

2 September 2017

Beatrice Wyse

3

1 reference

2 September 2017

Mehmood Khan

5

1 reference

2 September 2017

A. R. Diani

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14532171

19 March 2024

F. T. Murray

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14532171

19 March 2024

language of work or name

1 reference

7 October 2003

1 reference

full work available at URL

2 September 2017

https://www.physiology.org/doi/pdf/10.1152/ajpendo.00331.2003

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.00331.2003

American Journal of Physiology - Endocrinology and Metabolism

19 March 2024

published in

1 reference

2 September 2017

286

1 reference

2 September 2017

1

1 reference

2 September 2017

E116-22

1 reference

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

2 September 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Influence of the mutation "diabetes" on insulin release and islet morphology in mice of different genetic backgrounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Obese and diabetes: Two mutant genes causing diabetes-obesity syndromes in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

The influence of genetic background on the expression of the obese (ob) gene in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Overexpression of Cu2+/Zn2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Studies in the diabetic mutant mouse. II. Electron microscopy of pancreatic islets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Insulin resistance and beta-cell function--a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Changes in pancreatic islets in aging Wistar and Zucker rats: a histochemical and ultrastructural morphometric study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Effects of the obese gene product on body weight regulation in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis model assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1beta cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Studies of a Simplified Plasma Insulin Immunoassay Using Cellulose Powder

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00331.2003

Streptozotocin-induced diabetes in the Chinese hamster. Biochemical and endocrine disorders

21 January 2018

7

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.00331.2003

Analysis of pancreatic islet cells and hormone content in the spontaneously diabetic KKAy mouse by morphometry, immunocytochemistry and radioimmunoassay

19 March 2024

13

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.00331.2003

Expression of peroxisome proliferator-activated receptor γ (PPARγ) in normal human pancreatic islet cells

19 March 2024

14

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.00331.2003

General Survey of Diabetic Features of Yellow KK Mice

19 March 2024

19

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.00331.2003

The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus

19 March 2024

20

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.00331.2003

Studies in the diabetic mutant mouse. I. Light microscopy and radioautography of pancreatic islets

19 March 2024

23

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.00331.2003

Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study

19 March 2024

27

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.00331.2003

Insulin resistance and beta-cell function - a clinical perspective

19 March 2024

28

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.00331.2003

UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years

19 March 2024

29

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.00331.2003

Morphological Observations on Pancreatic Islets of Spontaneous Diabetic Mice, “Yellow KK”

19 March 2024

41

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.00331.2003

19 March 2024

Identifiers

1 reference

2 September 2017

1 reference